Company: NCEL
Filing Date: 2025-09-25
Form Type: F-1
Source: 0001213900-25-091697
Chunk: 7

Company: NewcelX Ltd.
Filing Date: 2025-09-25
Form: F-1
Chunk 7
---
 issued the Selling Shareholder a pre-funded warrant to purchase 192,308
Common Shares as Commitment Shares. The Purchase Agreement contains customary registration rights, representations, warranties, conditions
and indemnification obligations by each party. The representations, warranties and covenants contained in the Purchase Agreements were
made only for purposes of the Purchase Agreements and as of specific dates, were solely for the benefit of the parties to such agreements
and are subject to certain important limitations.

We have the right to terminate the Purchase Agreement at any time after Commencement, at no cost or penalty, upon 10 days’ prior written notice. No termination of the Purchase Agreement will affect the registration rights provisions contained within the Purchase Agreement, which will survive any termination of the Purchase Agreement.

Agreement and Plan of Merger with Kadimastem

On November 4, 2024, the Company,
NLS Pharmaceutics (Israel) Ltd., an Israeli company and a wholly-owned subsidiary of the Company (the “Merger Sub”) and Kadimastem
Ltd. an Israeli publicly traded company limited by shares (TASE: KDST)(“Kadimastem”), entered into an Agreement and Plan of
Merger (the “Merger Agreement”). Pursuant to the Merger Agreement, subject to the terms and conditions set forth therein,
the Merger Sub will merge with and into Kadimastem, with Kadimastem continuing as the surviving corporation in the Merger and a wholly-owned
subsidiary of NLS (the “Merger”). The Merger will occur in the following order: (i) at the Effective Time (as defined in the
Merger Agreement), Kadimastem will be a wholly-owned subsidiary of Merger Sub, and (ii) following the Effective Time, Kadimastem and Merger
Sub will be combined in a statutory consolidation where Merger Sub will merge with and into Kadimastem, with Kadimastem continuing as
the surviving corporation in the Merger and a wholly-owned subsidiary of NLS. In the Merger, all of the issued and outstanding Kadimastem’s
ordinary shares (“Kadimastem Ordinary Shares”), immediately prior to the Effective Time shall no longer be outstanding and
shall be exchanged for and automatically converted into the right to receive from NLS that certain number of fully paid and nonassessable
Common Shares (the “Common Shares”) as calculated in accordance with the terms of the Merger Agreement